Analytical Data
-
Gene name
nadA
- Application
-
Alternative Names
nadA；Conidial surface nicotinamide adenine dinucleotide glycohydrolase nadA
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11458
-
Expression Region
1-347aa
-
AA Sequence
MSVMFDPDTA IYPFPPKPTP LSIDEKAYYR EKIKRLLKER NAVMVAHYYT DPEIQQLAEE TGGCISDSLE MARFGAKHPA STLLVAGVRF MGETAKILSP EKTILMPTLQ AECSLDLGCP VEEFNAFCDA HPDRTVVVYA NTSAAVKARA DWVVTSSIAV ELIDHLDSLG EKIIWAPDKH LGRYVQKQTG GDILCWQGAC IVHDEFKTQA LTRLQEEYPD AAILVHPESP QAIVDMADAV GSTSQLIAAA KTLPHQRLIV ATDRGIFYKM QQAVPDKELL EAPTAGEGAT CRSCAHCPWM AMNGLQAIAE ALEQEGSNHE VHVDERLRER ALVPLNRMLD FAATLRG
-
Molecular Weight
38.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NadA is a prominent virulence factor associated with certain pathogenic bacteria, notably the Neisseria species, which includes Neisseria meningitidis, a major cause of bacterial meningitis. The nadA gene encodes a surface-exposed protein that plays a crucial role in the adhesion of bacteria to host cells, facilitating infection and evasion of the immune response. Given its significance in pathogenesis, NadA has become a target for vaccine development, as eliciting an immune response against this protein could provide protective effects against meningococcal disease. Research on recombinant NadA proteins has been focused on understanding its structure, function, and immunogenicity. Scientists are utilizing various immunological techniques to generate and characterize these recombinant proteins, aiming to elucidate their potential as vaccine candidates. The study of nadA and its recombinant forms not only enhances our understanding of bacterial pathogenesis but also contributes to the development of effective preventive strategies against meningococcal infections, which remain a global health concern. This research underscores the importance of exploring bacterial proteins to innovate in vaccine technology, thereby providing insights that may lead to improved public health outcomes.
